

Clinical trials of Pharmuka

TrialResults-center www.trialresultscenter.org

1 thrombosis prevention

Trial	Treatments	Patients	Trials design and methods
Pharmuka vs placebo			
Dahan , 1986 n=132/131 follow-up: <10 days	Pharmuka 60 mg once daily, Until hospital discharge, <=10 days versus placebo	Congestive heart failure (NYHA IIIIV), acute or respiratory infectious disease	Parallel groups double blind

More details and results :

- antithrombotics for thrombosis prevention in medical patients at <http://www.trialresultscenter.org/go-Q87>
- LMWH for thrombosis prevention in medical patients at <http://www.trialresultscenter.org/go-Q719>

References

Dahan, 1986:

Dahan R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler M, Segrestaa JM Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis 1986;16:159-64 [[3710294](#)]